FDA Expands Finerenone to Type 1 Diabetes CKD

Company Bayer Event Type FDA Approval (Indication Expansion) Modality Selective Non-Steroidal Mineralocorticoid-Receptor Antagonist Asset Finerenone (Kerendia) Disease Area Chronic Kidney Disease Associated With Type 1 Diabetes Summary FDA approved finerenone (Kerendia) to reduce urine albumin-to-creatinine ratio in adults with chronic kidney disease associated with type…